Jane Street’s Denali Therapeutics DNLI Stock Holding History

Jane Street’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80,500	Closed	-$1.55M	–	11854
2026 Q1	$1.55M	Buy	80,500 +69,900	+659%	+$1.39M	﹤0.01%	5575
2025 Q4	$175K	Sell	10,600 -13,800	-57%	-$233K	﹤0.01%	9834
2025 Q3	$354K	Sell	24,400 -27,300	-53%	-$392K	﹤0.01%	8581
2025 Q2	$723K	Buy	+51,700	New	+$728K	﹤0.01%	6238
2024 Q4	–	Sell	-16,100	Closed	-$469K	–	9623
2024 Q3	$469K	Sell	16,100 -5,900	-27%	-$146K	﹤0.01%	7300
2024 Q2	$511K	Buy	+22,000	New	+$422K	﹤0.01%	6995
2023 Q4	–	Sell	-20,700	Closed	-$427K	–	9283
2023 Q3	$427K	Buy	20,700 +3,300	+19%	+$83.7K	﹤0.01%	6524
2023 Q2	$513K	Buy	+17,400	New	+$489K	﹤0.01%	6283
2022 Q3	–	Sell	-7,400	Closed	-$218K	–	9831
2022 Q2	$218K	Buy	+7,400	New	+$194K	﹤0.01%	8069
2021 Q1	–	Sell	-7,900	Closed	-$662K	–	9169
2020 Q4	$662K	Buy	+7,900	New	+$478K	﹤0.01%	5320

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's DNLI Position: Q2 2026 in Review

Jane Street sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 32,147 shares — an estimated $661K sold.

Jane Street first reported a position in DNLI in Q3 2018 and held it in 25 quarters. The position peaked at $10.8M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Jane Street reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 32,147 Denali Therapeutics shares in Q2 2026, an estimated $661K.
Jane Street first reported a position in Denali Therapeutics in Q3 2018 and held it in 25 quarters.
Jane Street's Denali Therapeutics position peaked at $10.8M in Q3 2024.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.